Such bacteria could kill up to 10 million people per year and cost up to $100 trillion by 2050 worldwide, according to the findings, which were reported by Reuters.
Jim O’Neill, former chief economist for Goldman Sachs, led the study and said the $100 trillion impact of drug-resistant superbugs may be on the conservative side.
“As big as that number might seem, it almost definitely underestimates the true economic cost,” he said, according to the report.
More articles on antibiotic resistance:
The easiest way to reduce antibiotic prescribing in children’s hospitals
Merck to acquire antibiotic developer Cubist for $9.5B
Nebraska Methodist Hospital to add bacteria-resistant curtains
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
